Lymphoma  >>  glucopyranosyl lipid A (G100)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glucopyranosyl lipid A (G100) / Merck (MSD)
NCT03742804: Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma

Withdrawn
2
0
NA
Intratumoral G100
Yale University
Lymphoma, T-Cell, Cutaneous
12/19
12/22
NCT02501473 / 2015-005382-23: Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Hourglass Jan 2020 - Dec 2020 : From trial for non-follicular B-cell lymphomas
Checkmark From P1/2 trial in combination with Keytruda at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From P1/2 trial in combination with Keytruda at ASH 2018 [screenshot]
Checkmark Presentation of long term follow-up data from P2 portion of P1/2 trial
Dec 2018 - Dec 2018: Presentation of long term follow-up data from P2 portion of P1/2 trial
More
Terminated
1/2
52
NA
G100, glucopyranosyl lipid A stable emulsion, GLA-SE, Pembrolizumab, Keytruda, MK-3475, Rituximab
Immune Design, Merck Sharp & Dohme LLC
Follicular Low Grade Non-Hodgkin's Lymphoma
08/19
08/19

Download Options